<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />


<meta name="author" content="Your Team Name" />

<meta name="date" content="2025-05-02" />

<title>Estimand Selection for Real-World Evidence: The SOF vs Non-SOF AKI Case Study</title>

<script src="site_libs/header-attrs-2.29/header-attrs.js"></script>
<script src="site_libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/cosmo.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="site_libs/navigation-1.1/tabsets.js"></script>
<link href="site_libs/highlightjs-9.12.0/textmate.css" rel="stylesheet" />
<script src="site_libs/highlightjs-9.12.0/highlight.js"></script>

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>









<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-default  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">HOME</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li>
  <a href="step1v2.html">Roadmap step 1-alt</a>
</li>
<li>
  <a href="step1.html">Roadmap step 1</a>
</li>
<li>
  <a href="step2.html">Roadmap step 2</a>
</li>
<li>
  <a href="step3.html">Roadmap step 3</a>
</li>
<li>
  <a href="step4.html">Roadmap step 4</a>
</li>
<li>
  <a href="step5.html">Roadmap step 5</a>
</li>
<li>
  <a href="RWE_tutorial.html">Introduction: TL Roadmap in RWE</a>
</li>
<li>
  <a href="case_study_AKI.html">Case study intro: Hep. C and AKI</a>
</li>
<li>
  <a href="PS_analysis.html">Propensity score matching analysis</a>
</li>
<li>
  <a href="TMLE_analysisV4.html">Targeted learning analysis4</a>
</li>
<li>
  <a href="appendix.html">Appendix</a>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">Estimand Selection for Real-World Evidence:
The SOF vs Non-SOF AKI Case Study</h1>
<h4 class="author">Your Team Name</h4>
<h4 class="date">2025-05-02</h4>

</div>

<div id="TOC">
<ul>
<li><a href="#background" id="toc-background"><span
class="toc-section-number">1</span> Background</a>
<ul>
<li><a href="#case-study-sof-vs-non-sof-acute-kidney-injury-aki"
id="toc-case-study-sof-vs-non-sof-acute-kidney-injury-aki"><span
class="toc-section-number">1.1</span> Case Study: SOF vs Non-SOF Acute
Kidney Injury (AKI)</a>
<ul>
<li><a href="#study-data-and-population"
id="toc-study-data-and-population"><span
class="toc-section-number">1.1.1</span> Study Data and
Population</a></li>
<li><a href="#endpoint-definition" id="toc-endpoint-definition"><span
class="toc-section-number">1.1.2</span> Endpoint Definition</a></li>
</ul></li>
</ul></li>
<li><a href="#defining-the-estimand"
id="toc-defining-the-estimand"><span class="toc-section-number">2</span>
Defining the Estimand</a>
<ul>
<li><a href="#strategies-for-intercurrent-events"
id="toc-strategies-for-intercurrent-events"><span
class="toc-section-number">2.1</span> Strategies for Intercurrent
Events</a>
<ul>
<li><a href="#treatment-policy" id="toc-treatment-policy"><span
class="toc-section-number">2.1.1</span> 1. Treatment-policy</a></li>
<li><a href="#while-on-treatment-recommended"
id="toc-while-on-treatment-recommended"><span
class="toc-section-number">2.1.2</span> 2. While-on-treatment
(Recommended)</a></li>
<li><a href="#hypothetical" id="toc-hypothetical"><span
class="toc-section-number">2.1.3</span> 3. Hypothetical</a></li>
<li><a href="#principal-stratum" id="toc-principal-stratum"><span
class="toc-section-number">2.1.4</span> 4. Principal Stratum</a></li>
</ul></li>
</ul></li>
<li><a href="#estimation-methods" id="toc-estimation-methods"><span
class="toc-section-number">3</span> Estimation Methods</a>
<ul>
<li><a href="#target-trial-emulation"
id="toc-target-trial-emulation"><span
class="toc-section-number">3.1</span> Target Trial Emulation</a></li>
<li><a href="#targeted-maximum-likelihood-estimation-tmle"
id="toc-targeted-maximum-likelihood-estimation-tmle"><span
class="toc-section-number">3.2</span> Targeted Maximum Likelihood
Estimation (TMLE)</a></li>
<li><a href="#sensitivity-analyses" id="toc-sensitivity-analyses"><span
class="toc-section-number">3.3</span> Sensitivity Analyses</a></li>
</ul></li>
<li><a href="#interpretation-and-communication-of-results"
id="toc-interpretation-and-communication-of-results"><span
class="toc-section-number">4</span> Interpretation and Communication of
Results</a></li>
<li><a href="#regulatory-considerations"
id="toc-regulatory-considerations"><span
class="toc-section-number">5</span> Regulatory Considerations</a></li>
<li><a href="#summary-and-recommendations"
id="toc-summary-and-recommendations"><span
class="toc-section-number">6</span> Summary and Recommendations</a></li>
</ul>
</div>

<div id="background" class="section level1" number="1">
<h1><span class="header-section-number">1</span> Background</h1>
<p>Regulatory and methodological developments, particularly the ICH
E9(R1) Addendum on estimands, emphasize the importance of clearly
defining the estimand—what precisely the study aims to estimate—in
clinical trials and increasingly in real-world evidence (RWE) studies.
The estimand explicitly addresses the scientific question by defining
five elements:</p>
<ul>
<li>Population</li>
<li>Treatment conditions</li>
<li>Endpoint</li>
<li>Handling of intercurrent events</li>
<li>Population-level summary measure</li>
</ul>
<p>Proper estimand selection guides study design, data collection,
analysis, and reporting, making the results more interpretable and
actionable, particularly in regulatory contexts.</p>
<div id="case-study-sof-vs-non-sof-acute-kidney-injury-aki"
class="section level2" number="1.1">
<h2><span class="header-section-number">1.1</span> Case Study: SOF vs
Non-SOF Acute Kidney Injury (AKI)</h2>
<p>We illustrate estimand selection through a real-world evidence (RWE)
analysis comparing the risk of acute kidney injury (AKI) among chronic
hepatitis C virus (HCV) patients treated with sofosbuvir
(SOF)-containing versus non-SOF direct-acting antiviral (DAA) regimens.
AKI risk has emerged as a safety signal of interest from post-marketing
surveillance.</p>
<div id="study-data-and-population" class="section level3"
number="1.1.1">
<h3><span class="header-section-number">1.1.1</span> Study Data and
Population</h3>
<p>The data source is HealthVerity, containing claims linked with
electronic medical records (EMR). The population includes U.S. adults
initiating reimbursed SOF or non-SOF DAA regimens between January 2016
and September 2023. Baseline covariates are captured 365 days prior to
treatment initiation (index date).</p>
</div>
<div id="endpoint-definition" class="section level3" number="1.1.2">
<h3><span class="header-section-number">1.1.2</span> Endpoint
Definition</h3>
<p>The primary endpoint is defined as time from index date to the first
occurrence of AKI, identified through relevant ICD-10 codes (e.g.,
N17.x, N19, R34, R94.4). Patients were followed until AKI occurrence,
death, disenrollment, switching/stopping DAA regimen plus 31 days, or
end of study period (September 21, 2023).</p>
</div>
</div>
</div>
<div id="defining-the-estimand" class="section level1" number="2">
<h1><span class="header-section-number">2</span> Defining the
Estimand</h1>
<p>According to the ICH E9(R1) framework, we explicitly specify the
estimand by clearly defining population, treatment, endpoint, handling
of intercurrent events, and summary measure:</p>
<table>
<colgroup>
<col width="31%" />
<col width="68%" />
</colgroup>
<thead>
<tr class="header">
<th>Estimand Element</th>
<th>SOF vs Non-SOF AKI Case Study Definition</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Population</td>
<td>US adult chronic HCV patients initiating SOF or non-SOF DAA</td>
</tr>
<tr class="even">
<td>Treatment</td>
<td>SOF-containing vs. Non-SOF-containing DAA regimens</td>
</tr>
<tr class="odd">
<td>Endpoint</td>
<td>Time to first AKI event</td>
</tr>
<tr class="even">
<td>Intercurrent events</td>
<td>Treatment discontinuation or switching</td>
</tr>
<tr class="odd">
<td>Summary Measure</td>
<td>Hazard Ratio (HR) or Risk Difference (RD) at specified times</td>
</tr>
</tbody>
</table>
<div id="strategies-for-intercurrent-events" class="section level2"
number="2.1">
<h2><span class="header-section-number">2.1</span> Strategies for
Intercurrent Events</h2>
<p>Four main strategies from the estimand framework:</p>
<div id="treatment-policy" class="section level3" number="2.1.1">
<h3><span class="header-section-number">2.1.1</span> 1.
Treatment-policy</h3>
<ul>
<li><strong>Definition</strong>: Compares initiators irrespective of
subsequent changes (stopping/switching).</li>
<li><strong>Interpretation</strong>: Effect of assigning SOF regimen,
regardless of adherence or switches.</li>
<li><strong>Strengths</strong>: Reflects pragmatic, real-world policy
decisions.</li>
<li><strong>Weaknesses</strong>: Interpretation muddled if switching
common.</li>
</ul>
</div>
<div id="while-on-treatment-recommended" class="section level3"
number="2.1.2">
<h3><span class="header-section-number">2.1.2</span> 2.
While-on-treatment (Recommended)</h3>
<ul>
<li><strong>Definition</strong>: Follow-up censored at treatment
switching/stopping.</li>
<li><strong>Interpretation</strong>: Effect of continuous treatment
exposure.</li>
<li><strong>Strengths</strong>: Relevant for safety signals during
active exposure.</li>
<li><strong>Weaknesses</strong>: Requires careful modeling of
censoring.</li>
</ul>
</div>
<div id="hypothetical" class="section level3" number="2.1.3">
<h3><span class="header-section-number">2.1.3</span> 3.
Hypothetical</h3>
<ul>
<li><strong>Definition</strong>: Estimates risk if no switching/stopping
occurred.</li>
<li><strong>Interpretation</strong>: Biological or pharmacological
effect without interruption.</li>
<li><strong>Strengths</strong>: Pure causal interpretation.</li>
<li><strong>Weaknesses</strong>: Unrealistic scenario; complex modeling
assumptions.</li>
</ul>
</div>
<div id="principal-stratum" class="section level3" number="2.1.4">
<h3><span class="header-section-number">2.1.4</span> 4. Principal
Stratum</h3>
<ul>
<li><strong>Definition</strong>: Effect within subgroup who would never
switch/stop.</li>
<li><strong>Interpretation</strong>: Efficacy in adherent subgroup.</li>
<li><strong>Strengths</strong>: Clear subgroup interpretation.</li>
<li><strong>Weaknesses</strong>: Difficult to identify subgroup
reliably; limited generalizability.</li>
</ul>
<p>Given the clinical and regulatory context for AKI, the
<strong>while-on-treatment</strong> estimand is recommended.</p>
</div>
</div>
</div>
<div id="estimation-methods" class="section level1" number="3">
<h1><span class="header-section-number">3</span> Estimation Methods</h1>
<div id="target-trial-emulation" class="section level2" number="3.1">
<h2><span class="header-section-number">3.1</span> Target Trial
Emulation</h2>
<p>To align RWE analyses with causal inference principles, we use a
target trial emulation approach:</p>
<ol style="list-style-type: decimal">
<li>Clearly articulate estimand (done above).</li>
<li>Emulate eligibility, treatment assignment, and follow-up strategies
from randomized trials.</li>
<li>Adjust for confounding and censoring biases explicitly using robust
estimation methods (e.g., TMLE).</li>
</ol>
</div>
<div id="targeted-maximum-likelihood-estimation-tmle"
class="section level2" number="3.2">
<h2><span class="header-section-number">3.2</span> Targeted Maximum
Likelihood Estimation (TMLE)</h2>
<p>TMLE is recommended due to its double robustness and incorporation of
machine learning:</p>
<ul>
<li>Combines estimation of the outcome mechanism and treatment
assignment mechanism (propensity scores).</li>
<li>Employs Super Learner ensemble modeling for flexible nuisance
parameter estimation.</li>
<li>Provides robust inference with valid confidence intervals.</li>
</ul>
<pre class="r"><code>library(tmle)
library(SuperLearner)

# Example pseudo-code (specific details depend on data structure)
tmle_out &lt;- tmle(Y = AKI_event,
                 A = Treatment (SOF vs non-SOF),
                 W = baseline_covariates,
                 family = &quot;binomial&quot;,
                 Q.SL.library = c(&quot;SL.glm&quot;, &quot;SL.randomForest&quot;),
                 g.SL.library = c(&quot;SL.glm&quot;, &quot;SL.randomForest&quot;))

summary(tmle_out)</code></pre>
</div>
<div id="sensitivity-analyses" class="section level2" number="3.3">
<h2><span class="header-section-number">3.3</span> Sensitivity
Analyses</h2>
<ul>
<li>Informative censoring: Apply inverse-probability weighting.</li>
<li>Alternative estimands (treatment-policy, hypothetical
scenario).</li>
<li>Competing risks: Conduct Fine-Gray or cause-specific hazard
analyses.</li>
<li>Evaluate unmeasured confounding via E-values.</li>
</ul>
</div>
</div>
<div id="interpretation-and-communication-of-results"
class="section level1" number="4">
<h1><span class="header-section-number">4</span> Interpretation and
Communication of Results</h1>
<ul>
<li>Clearly state the chosen estimand and its clinical
implications.</li>
<li>Present both TMLE and traditional survival (e.g., Cox regression)
estimates for transparency.</li>
<li>Explicitly acknowledge limitations and assumptions underpinning
causal interpretation.</li>
</ul>
</div>
<div id="regulatory-considerations" class="section level1" number="5">
<h1><span class="header-section-number">5</span> Regulatory
Considerations</h1>
<p>The FDA and EMA increasingly expect clarity in estimand specification
in RWE submissions. The while-on-treatment estimand closely aligns with
regulatory interests for post-market safety signals, especially those
emerging under continuous treatment exposure.</p>
</div>
<div id="summary-and-recommendations" class="section level1" number="6">
<h1><span class="header-section-number">6</span> Summary and
Recommendations</h1>
<ul>
<li>Define estimands clearly at the outset of analyses.</li>
<li>The while-on-treatment estimand is particularly relevant for
evaluating acute safety signals like AKI in real-world treatment
settings.</li>
<li>Adopt TMLE with Super Learner methods for robust causal inference,
explicitly handling censoring and confounding.</li>
<li>Include sensitivity analyses for robustness assessment.</li>
</ul>
<p>Explicit estimand definition coupled with robust statistical methods
like TMLE not only ensures clarity and scientific rigor but also
enhances regulatory relevance and interpretability.</p>
</div>




</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
